<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519359</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-01</org_study_id>
    <nct_id>NCT04519359</nct_id>
  </id_info>
  <brief_title>Biomarkers Guided Stopping NAs Treatment</brief_title>
  <official_title>Novel Biomarkers Guided Stopping Nucleos(t)Ide Analogues After Long-term Virologic Suppression in CHB Patients: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss&#xD;
      in subjects who stop nucles(t)ide analogues (NAs) (Stop arm) compared to subjects who&#xD;
      continue (Continue arm) Only subjects who already are on treatment with ETV, TDF or TAF&#xD;
      monotherapy, and have achieved sustained virologic suppression (&lt;20 IU/mL), HBeAg negativity,&#xD;
      normal ALT for more than 1 year (pretreatment HBeAg + pts) or 3 years (pretreatment HBeAg -&#xD;
      pts), plus qHBsAg &lt;200 IU/mL, and HBV RNA or HBcrAg negativity will be included in this&#xD;
      study. One treatment arm will stop the NAs therapy while the other treatment arm will&#xD;
      continue the NAs therapy. Participants in the Stop arm will be monitored very closely with&#xD;
      special focus on clinical relapse. If any participant in the Stop NAs arm exceeds one or more&#xD;
      predefined limits for such flares or relapses, NAs treatment will be reinstituted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With HBsAg Loss at Week 72 in Both Study Arms</measure>
    <time_frame>Week 72</time_frame>
    <description>HBsAg loss is defined as qualitative HBsAg result changing from positive at baseline (BL) to negative at any post-baseline visit. Proportions are based on a Kaplan-Meier estimate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Sustained Disease Remission at Week 72 in Both Study Arms</measure>
    <time_frame>Week 72</time_frame>
    <description>Sustained Disease Remission is defined as HBeAg negativity, HBV DNA &lt;2000 IU/mL and ALT normalization at any post-baseline visit. Proportions are based on a Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Clinical Relapse at Week 72 in Both Study Arms</measure>
    <time_frame>Week 72</time_frame>
    <description>Clinical Relapse is defined as HBV DNA &gt;2000 IU/mL and ALT &gt;2 ULN at any post-baseline visit. Proportions are based on a Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Virologic Relapse at Week 72 in Both Study Arms</measure>
    <time_frame>Week 72</time_frame>
    <description>Virologic Relapse is defined as HBV DNA &gt;2000 IU/mL at two consecutive timepoints [at least 14 days apart] at any post-baseline visit. Proportions are based on a Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantitative HBsAg (IU/mL) in Both Study Arms</measure>
    <time_frame>Week 72</time_frame>
    <description>The analyses were summarized by 3 treatment subgroups: Stop NAs (NAs-Free), Restart NAs, and Continue NAs When participant randomized in the Stop NAs group restarted NAs therapy, that participant was considered part of the Restart NAs group from that point forward. For Restart NAs group, baseline is defined as the last available record on or prior to the restart date of NAs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Stop Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stop NAs therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continue NAs therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop NAs therapy</intervention_name>
    <description>Stop NAs therapy</description>
    <arm_group_label>Stop Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years of old, male or female&#xD;
&#xD;
          -  Chronic hepatitis B patients&#xD;
&#xD;
          -  Received continuous ETV, TDF or TAF therapy for at least 1 year prior to screening and&#xD;
             at screening&#xD;
&#xD;
          -  For patients with Hepatitis B e Antigen (HBeAg)-positive at the beginning of NAs&#xD;
             therapy, documented hepatitis B virus &lt;20 IU/mL, HBeAg seroconversion and ALT&#xD;
             normalization for at least 1 year prior to screening and at screening&#xD;
&#xD;
          -  For patients with HBeAg-negative at the beginning of NAs therapy, documented hepatitis&#xD;
             B virus &lt;20 IU/mL, and ALT normalization for at least 3 year prior to screening and at&#xD;
             screening&#xD;
&#xD;
          -  &lt;= 9 kPa on Fibroscan assessment&#xD;
&#xD;
          -  qHBsAg &lt;200 IU/mL within 24 weeks prior to screening&#xD;
&#xD;
          -  HBV RNA or HBcrAg negativity within 24 weeks prior to screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Experience of IFN treatment within 1 year prior to screening&#xD;
&#xD;
          -  Known cirrhosis&#xD;
&#xD;
          -  History of decompensated liver disease&#xD;
&#xD;
          -  History of clinical hepatic decompensation in the judgement of the investigator&#xD;
&#xD;
          -  Evidence of hepatocellular carcinoma&#xD;
&#xD;
          -  Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis&#xD;
             C virus, or hepatitis D infection&#xD;
&#xD;
          -  Known hypersensitivity to TDF, its metabolites, or formulation excipients&#xD;
&#xD;
          -  History of malignant disease&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
          -  Females wishing to became pregnant during the duration of the study&#xD;
&#xD;
          -  Subjects participating in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jian Sun, MD</last_name>
    <phone>86-20-62787432</phone>
    <email>doctorsunjian@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Ma, MD</last_name>
      <email>mahongmd@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiying Rao, MD</last_name>
      <email>rao.huiying@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>No. 1 Hospital affiliated to Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhang Gao, MD</last_name>
      <email>gyhd0165@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoguang Dou, MD</last_name>
      <email>guang40@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Xie, MD</last_name>
      <email>xieqingrjh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

